A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
ABSTRACTObjectives: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives.Methods: This was an observational, multicenter, ambispective stu...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2178997 |
| _version_ | 1797829797518245888 |
|---|---|
| author | Rafael Ríos-Tamayo Juan Alfons Soler Ricarda García-Sánchez Ernesto Pérez Persona Mario Arnao Antoni García-Guiñón Abel Domingo Miriam González-Pardo Javier de la Rubia María Victoria Mateos |
| author_facet | Rafael Ríos-Tamayo Juan Alfons Soler Ricarda García-Sánchez Ernesto Pérez Persona Mario Arnao Antoni García-Guiñón Abel Domingo Miriam González-Pardo Javier de la Rubia María Victoria Mateos |
| author_sort | Rafael Ríos-Tamayo |
| collection | DOAJ |
| description | ABSTRACTObjectives: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives.Methods: This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb.Results: A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected.Conclusions: The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials. |
| first_indexed | 2024-04-09T13:25:57Z |
| format | Article |
| id | doaj.art-fa57cbe5cfd646a0a1342153e985451e |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-04-09T13:25:57Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-fa57cbe5cfd646a0a1342153e985451e2023-05-10T11:08:17ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2023.2178997A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS studyRafael Ríos-Tamayo0Juan Alfons Soler1Ricarda García-Sánchez2Ernesto Pérez Persona3Mario Arnao4Antoni García-Guiñón5Abel Domingo6Miriam González-Pardo7Javier de la Rubia8María Victoria Mateos9Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SpainDepartment of Hematology, Hospital Universitari Parc Taulí de Sabadell, Catalonia, SpainDepartment of Hematology, Hospital Virgen de la Victoria, Málaga, SpainDepartment of Hematology, Hospital Universitario de Navarra, Pamplona, SpainDepartment of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, SpainDepartment of Hematology, Hospital Universitari Arnau de Vilanova, Lleida, SpainDepartment of Hematology, Hospital General de Granollers, SpainMedical Department, Janssen-Cilag España, SpainHospital Universitari i Politècnic La Fe, Valencia, SpainInstituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Hospital Universitario de Salamanca, Salamanca, SpainABSTRACTObjectives: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives.Methods: This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb.Results: A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected.Conclusions: The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials.https://www.tandfonline.com/doi/10.1080/16078454.2023.2178997Relapsed-refractory multiple myelomareal-worldmonoclonal antibodiesdaratumumabstandard of care |
| spellingShingle | Rafael Ríos-Tamayo Juan Alfons Soler Ricarda García-Sánchez Ernesto Pérez Persona Mario Arnao Antoni García-Guiñón Abel Domingo Miriam González-Pardo Javier de la Rubia María Victoria Mateos A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study Hematology Relapsed-refractory multiple myeloma real-world monoclonal antibodies daratumumab standard of care |
| title | A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study |
| title_full | A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study |
| title_fullStr | A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study |
| title_full_unstemmed | A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study |
| title_short | A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study |
| title_sort | glimpse into relapsed refractory multiple myeloma treatment in real world practice in spain the geminis study |
| topic | Relapsed-refractory multiple myeloma real-world monoclonal antibodies daratumumab standard of care |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2023.2178997 |
| work_keys_str_mv | AT rafaelriostamayo aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT juanalfonssoler aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT ricardagarciasanchez aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT ernestoperezpersona aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT marioarnao aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT antonigarciaguinon aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT abeldomingo aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT miriamgonzalezpardo aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT javierdelarubia aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT mariavictoriamateos aglimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT rafaelriostamayo glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT juanalfonssoler glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT ricardagarciasanchez glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT ernestoperezpersona glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT marioarnao glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT antonigarciaguinon glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT abeldomingo glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT miriamgonzalezpardo glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT javierdelarubia glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy AT mariavictoriamateos glimpseintorelapsedrefractorymultiplemyelomatreatmentinrealworldpracticeinspainthegeminisstudy |